ANI Pharmaceuticals Insider File: $4.21M Sale of 47,010 Common Shares

Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) notice reports a proposed sale of 47,010 shares of common stock via Merrill Lynch on 08/14/2025 with an aggregate market value of $4,206,603.82. The shares represent part of the outstanding share count of 21,688,772. The filer states the shares were acquired on 11/19/2021 in a company buyout from ANI Pharmaceuticals and that the payment is a compensatory payment. No sales by the filer are reported in the prior three months. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.

Positive

• Full disclosure of the planned Rule 144 sale including broker, share count, and aggregate value
• Origin of shares documented payment nature stated as compensatory
• No sales in prior three months reported, clarifying recent insider disposition activity

Negative

• Insider-related sale of 47,010 shares valued at $4,206,603.82 may be viewed negatively by some investors
• Sale size equals roughly 0.217% of outstanding shares (47,010 of 21,688,772), representing a non-trivial single transaction

Insights

Securities Analyst

TL;DR: Proposed sale of 47,010 ANIP shares for $4.21M, acquired in a 2021 company buyout, appears to be a compensatory disposition disclosed under Rule 144.

The filing documents a planned Rule 144 sale of 47,010 common shares on 08/14/2025 through Merrill Lynch, valued at $4,206,603.82, against total outstanding shares of 21,688,772. The acquisition date is 11/19/2021 and the transaction is described as arising from a company buyout with the payment characterized as compensatory. There are no reported sales by the filer in the prior three months. For investors this is a routine compliance disclosure that provides transparency about an insider-related sale and the mechanics of the disposition.

Corporate Governance Expert

TL;DR: The Form 144 is a standard compliance disclosure signaling an insider-related sale with compensatory origins; no undisclosed material facts are claimed.

The notice includes required representations that the seller is unaware of undisclosed material adverse information and notes the sale will be executed via a registered broker. The origin of the shares is documented as a company buyout on 11/19/2021 and payment labeled compensatory, which clarifies the economic basis for the holding. Absence of other recent sales is explicitly stated. This filing improves governance transparency but does not, by itself, indicate company-level governance changes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Merrill Lynch 3455 Peachtree Road Atlanta GA 30326	47010	4206603.82	21688772	08/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2021	Company Buyout	ANI Pharmaceuticals			47010	08/14/2025	compensatory payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares of ANIP are being registered for sale?

The notice indicates 47,010 shares of ANIP common stock are proposed for sale.

When is the ANIP sale expected to occur?

The approximate date of sale listed is 08/14/2025.

What is the aggregate market value of the proposed ANIP sale?

The aggregate market value is listed as $4,206,603.82.

How were the ANIP shares originally acquired?

The shares were acquired on 11/19/2021 in a company buyout from ANI Pharmaceuticals.

Through which broker will the ANIP shares be sold?

The filing lists the broker as Merrill Lynch, 3455 Peachtree Road, Atlanta, GA.

Does the filer report other sales in the past three months?

The filing states Nothing to Report for securities sold during the past three months.